Astragaloside IV Reprograms Spatial Glycolytic Metabolism in Diabetic Kidney: A Microenvironment‐Targeted Immunometabolic Therapeutic Strategy

ABSTRACT Diabetic nephropathy (DN) remains a major cause of kidney failure, yet current therapies do not adequately target the spatially organized immunometabolic dysfunction that drives disease progression. Astragaloside IV (ASIV), a bioactive saponin derived from Astragalus membranaceus, exhibits...

Descripció completa

Dades bibliogràfiques

Autors principals:	Shi Qiu, Zhibo Wang, Sifan Guo, Dandan Xie, Ying Cai, Xian Wang, Yan Wang, Xiaodan Yu, Jinxuan Chai, Hong Yao, Chunsheng Lin, Qiang Yang, Yu Guan, Qiqi Zhao, Songqi Tang, Wenjie Sun, Yiqiang Xie, Aihua Zhang
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-05-01
Col·lecció:	Food Frontiers
Matèries:	diabetic human kidney glycolytic reprogramming macrophages microregion podocytes spatial transcriptomics
Accés en línia:	https://doi.org/10.1002/fft2.70295
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!